Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This trial is a multicenter, single-arm, phase 2 study of pembrolizumab in combination with
olaparib in recurrent or metastatic cervical cancer patients who had disease progression
during or after platinum-based chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Saitama Medical University International Medical Center
Collaborators:
Aichi Cancer Center Cancer Institute Hospital, Japan National Cancer Center, Japan Tokyo University